Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sophiris Eyes Another Phase III After Positive BPH Results

This article was originally published in Scrip

Executive Summary

Sophiris Bio Inc. bounced back from a negative interim efficacy report when the company revealed positive results from the Phase III PLUS-1 clinical trial for PRX302 (topsalysin) in the treatment of urinary tract symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, on Nov. 10.



Related Companies